VBI Vaccines announces second pivotal phase 3 study of Sci-B-Vac meets primary and secondary endpoints

VBI Vaccines has reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac, the company’s trivalent hepatitis B (HBV) vaccine, and comparing safety and immunogenicity of Sci-B-Vac to GlaxoSmithKline’s currently-marketed HBV vaccine, Engerix-B.